All the completed or ongoing clinical trials investigating MPS1 inhibitors have been performed on patients with advanced malignancies (solid tumors) or breast cancer, with no reference to treatments in patients with oral or head and neck cancer. This evidence concerns the gene TTK and head and neck cancer.